Search | Clinical Trials Finder

Conditions: Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions: canakinumab (anti IL-1beta), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Type 1 Diabetes Mellitus
Interventions: pioglitazone, Placebo control; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions: Imatinib Mesylate, Placebo (For imatinib mesylate); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Diabetes Mellitus, Type 1
Interventions: teplizumab 1 mg/mL; Drug
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: TOL-3021, TOL-3021 Placebo; Biological · Other
Lead sponsor: Tolerion, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 20 more

Conditions: Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: New-onset Type 1 Diabetes Mellitus
Interventions: Antithymocyte globulin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 35 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Oakland, California • San Diego, California + 6 more

Conditions: New-onset Type 1 Diabetes Mellitus
Interventions: Alefacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 35 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more

Conditions: Type1 Diabetes
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes
Interventions: High Dose SAB-142, Low Dose SAB-142, Placebo; Drug · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 5 Years to 40 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 23
States / cities: San Francisco, California • San Jose, California • Aurora, Colorado + 20 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 35 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more

Conditions: Type 1 Diabetes Mellitus
Interventions: GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog; Device · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Type 1 Diabetes, New Onset
Interventions: Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 9 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more

Conditions: Type 1 Diabetes
Interventions: Atorvastatin, Placebo; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 19 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Type 1 Diabetes (T1D)
Interventions: SAB-142, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 40 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions: Tocilizumab (TCZ), Placebo, Standard of Care; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more

Conditions: Type 1 Diabetes Mellitus
Interventions: cyclosporin and methotrexate; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 1994
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions: Lactiplantibacillus plantarum, Placebo; Dietary Supplement · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Inducing Remission in Type 1 Diabetes With Alefacept

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

A Research Trial of Aralast in New Onset Diabetes (RETAIN)

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

ATG-GCSF in New Onset Type 1 Diabetes

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Reducing Innate Inflammation in New Onset Type 1 Diabetes